Treats hypertension. ANDA 205670, held by Prinston. Fosinopril Sodium.
As of Nov 16, 2026, ANDA 205670 (Fosinopril Sodium), held by Prinston, was first approved by FDA on Aug 29, 2016, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Fosinopril sodium tablets are indicated for the treatment of hypertension. They may be used alone or in combination with thiazide diuretics. Fosinopril sodium tablets are indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics with or without digitalis (see DOSAGE AND ADMINISTRATION ). In using fosinopril sodium, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 29, 2016 | Original application | Approved | None posted |
| Fosinopril Sodium10MG · tablet;oral | Fosinopril Sodium | Rx |
| Fosinopril Sodium20MG · tablet;oral | Fosinopril Sodium | Rx |
| Fosinopril Sodium40MG · tablet;oral | Fosinopril Sodium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters